Committee for Orphan Medicinal Products May 2009 plenary meeting monthly report: Orphan medicinal product designation.

At its meeting of 5 May 2009, the European Medicines Agency's (EMEA) Committee for Orphan Medicinal Products (COMP) adopted five positive opinions recommending the following medicines for designation as orphan medicinal products to the European Commission: For the following medicines the EMEA review began on 6 Feb 2009 with an active review time of 89 days. Chimeric-anti-interleukin-6 monoclonal antibody for treatment of multiple myeloma, from Centocor BV. For the following medicines the EMEA review began on 9 Mar 2009 with an active …